153 related articles for article (PubMed ID: 38098600)
1. Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.
Nguyen LT; Pham GH; Vu PT; Yi HG
Ann Med Surg (Lond); 2023 Dec; 85(12):6274-6278. PubMed ID: 38098600
[TBL] [Abstract][Full Text] [Related]
2. A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.
Furui Y; Kurata T; Komori K; Uchida E; Miyairi Y; Chiba A; Ogiso Y; Sakashita K
Int Cancer Conf J; 2022 Oct; 11(4):280-285. PubMed ID: 36186222
[TBL] [Abstract][Full Text] [Related]
3. Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.
Imataki O; Uemura M; Fujita H; Kadowaki N
Mol Clin Oncol; 2022 Sep; 17(3):136. PubMed ID: 35949894
[TBL] [Abstract][Full Text] [Related]
4. Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
Lin Y; Cao Q; Hong A; Liang X
Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
[TBL] [Abstract][Full Text] [Related]
5. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review.
Huff D; Fortin Ensign S; Ryan MS; Palmer J; Munoz J
J Immunother Precis Oncol; 2023 Nov; 6(4):198-202. PubMed ID: 38143950
[TBL] [Abstract][Full Text] [Related]
6. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
7. Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review.
May JM; Waddle MR; Miller DH; Stross WC; Kaleem TA; May BC; Miller RC; Jiang L; Strong GW; Trifiletti DM; Chaichana KL; Reimer R; Tun HW; Peterson JL
Radiat Oncol; 2018 Sep; 13(1):167. PubMed ID: 30185195
[TBL] [Abstract][Full Text] [Related]
8. Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review.
Chen N; Ba W; Zhao D; Sheng L; Zhang X
Front Oncol; 2022; 12():816903. PubMed ID: 35299752
[TBL] [Abstract][Full Text] [Related]
9. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
10. A case of spindle cell dominant histiocytic sarcoma showing a complete remission after first-line chemotherapy with doxorubicin and ifosfamide.
Nakamura Y; Takemasa A; Kushima Y; Soda S; Ikeda N; Arai R; Chibana K; Nakazato Y; Yokose T; Shimizu Y; Niho S
J Chemother; 2020 Dec; 32(8):445-450. PubMed ID: 32431236
[TBL] [Abstract][Full Text] [Related]
11. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Fricke J; Mambetsariev I; Pharaon R; Subbiah S; Rajurkar S; Salgia R
Medicine (Baltimore); 2020 Nov; 99(46):e22323. PubMed ID: 33181636
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis.
Zhao Y; Deng Y; Jiang Y; Zheng W; Tan Y; Yang Z; Wang Z; Xu F; Cheng Z; Yuan L; Peng H
Front Immunol; 2023; 14():1127599. PubMed ID: 36969238
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Sachdeva M; Ngoi NYL; Lim D; Poon MLM; Thian YL; Lim YW; Lim SE; Tong P; Lum JHY; Ng J; Ilancheran A; Domingo EJ; Low JJH; Tan DSP
Onco Targets Ther; 2021; 14():3921-3928. PubMed ID: 34234460
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.
Gonugunta AS; von Itzstein MS; Gerber DE
J Med Case Rep; 2022 Jul; 16(1):289. PubMed ID: 35871685
[TBL] [Abstract][Full Text] [Related]
18. Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma.
Greally M; Agarwal R; El Dika I; Shamseddine A; El-Olayan A; Haibe Y; Paroder V; Shia J; Abou-Alfa GK; Ku GY
J Gastrointest Oncol; 2019 Apr; 10(2):367-372. PubMed ID: 31032108
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1.
Kim SR; Chun SH; Kim JH; Kim SY; Lee BI; Jung CK; Kang JH
Korean J Clin Oncol; 2020 Jun; 16(1):57-62. PubMed ID: 36945301
[TBL] [Abstract][Full Text] [Related]
20. Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.
Bloom BC; Augustyn A; Pezzi TA; Menon H; Mayo LL; Shah SJ; Schwartz DL; Chmura SJ; Johnson FM; Welsh JW; Chun SG
Front Oncol; 2019; 9():223. PubMed ID: 31024834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
